Seattle Genetics to Host Conference Call and Webcast on December 19, 2019 to Discuss PADCEVTM (enfortumab vedotin-ejfv) Appro...
December 18 2019 - 6:42PM
Business Wire
Seattle Genetics, Inc. (Nasdaq: SGEN) will host a conference
call and webcast on Thursday, December 19, 2019 to discuss the U.S.
Food and Drug Administration approval of PADCEVTM (enfortumab
vedotin-ejfv). Access to the event can be obtained as follows:
LIVE access on Thursday, December 19, 2019 6:00 a.m. Pacific
Time / 9:00 a.m. Eastern Time
- Telephone 800-367-2403 (domestic) or +1 334-777-6978
(international); conference ID 7236397
- Webcast available at www.seattlegenetics.com in the Investors
section
REPLAY access
- Telephone replay will be available beginning at approximately
9:00 a.m. PT on Thursday, December 19, 2019 through 9:00 a.m. PT on
Sunday, December 22, 2019 by calling 888-203-1112 (domestic) or +1
719-457-0820 (international); conference ID 7236397
- Webcast replay will be available on the Seattle Genetics
website at www.seattlegenetics.com in the Investors section
About Seattle Genetics
Seattle Genetics, Inc. is a global biotechnology company that
discovers, develops and commercializes transformative medicines
targeting cancer to make a meaningful difference in people’s lives.
ADCETRIS® (brentuximab vedotin) and PADCEVTM (enfortumab
vedotin-ejfv) use the company’s industry-leading antibody-drug
conjugate (ADC) technology designed to bring a powerful medicine
directly to cancer cells. ADCETRIS is approved for the treatment of
several types of CD30-expressing lymphomas, and PADCEV is approved
to treat adults with metastatic urothelial cancer. In addition,
investigational agent tucatinib, a small molecule tyrosine kinase
inhibitor, is in late-stage development for HER2-positive
metastatic breast cancer, and in clinical development for
metastatic colorectal cancer. The company is headquartered in
Bothell, Washington, and has offices in California, Switzerland and
the European Union. For more information on our robust pipeline,
visit www.seattlegenetics.com and follow @SeattleGenetics on
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191218005820/en/
Investors Peggy Pinkston (425) 527-4160
ppinkston@seagen.com
Media Monique Greer (425) 527-4641 mgreer@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024